NDA Submitted for Post-Cataract Surgery Inflammation Treatment

Current standard-of-care for inflammation follow surgery involves self-administering eye-drops for a period of weeks
Current standard-of-care for inflammation follow surgery involves self-administering eye-drops for a period of weeks

Icon Bioscience has submitted a New Drug Application to the Food and Drug Administration (FDA) for their product, Dexycu (IBI-10090), a novel treatment for inflammation associated with post-operative cataract surgery.  

Dexycu is a long-acting, biodegradable extended-release formulation of the anti-inflammatory agent dexamethasone, which is injected into the anterior chamber of the eye following cataract surgery. The one-time injection is administered with Icon's Varisome drug-delivery technology. 

Related Articles

Current standard-of-care for inflammation follow cataract surgery involves self-administering medicated eye-drops for a period of weeks. The proposed injection could possibly cut out dosing and adherence issues.

“Dexycu has been designed to improve the management of post-surgery inflammation by offering the physician the option of a single administration of the sustained-released anti-inflammatory agent at the site of action,” said Eric D. Donnenfeld, MD, Clinical Professor of Ophthalmology, NYU, and lead investigator for Dexycu clinical studies. 

For more information visit Iconbioscience.com.